Skip to content
Use caution Drug recall · FDA · Published September 29, 2026

Pfizer Recalls Levoxyl 175 mcg Tablets Due to Subpotent Drug Risk

Pfizer is recalling Levoxyl (levothyroxine sodium) 175 mcg tablets distributed nationwide due to confirmed out-of-specification assay results.

🇺🇸 FDA recall #D-0052-2027DrugPfizer ›
✎ GovInfoNow plain-language explainer

What happened, in plain English

Pfizer has recalled a specific lot of Levoxyl (levothyroxine sodium tablets, USP), 175 mcg strength. The recall was initiated because stability testing confirmed the drug is subpotent and out of specification. This means the medication may not deliver the full intended dose to patients. Read more at govinfonow.com/recall/1927672-pfizer-recalls-levoxyl-levothyroxine-sodium-tablets-usp-tablets-175-mcg.

Source Summary by GovInfoNow · govinfonow.com/recall/1927672-pfizer-recalls-levoxyl-levothyroxine-sodium-tablets-usp-tablets-175-mcg · Updated November 11, 2026 · FDA enforcement record: FDA #D-0052-2027

Cite this page

“Pfizer Recalls Levoxyl 175 mcg Tablets Due to Subpotent Drug Risk.” GovInfoNow, updated November 11, 2026. https://govinfonow.com/recall/1927672-pfizer-recalls-levoxyl-levothyroxine-sodium-tablets-usp-tablets-175-mcg. Based on FDA recall #D-0052-2027 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0052-2027%22&limit=1).

Why it’s dangerous

The hazard is a subpotent drug, meaning the active ingredient (levothyroxine sodium) is below the required specification during stability testing. For patients dependent on precise thyroid hormone levels, taking a subpotent tablet could result in inadequate treatment of their condition.

Who’s affected

Patients in the United States and Puerto Rico who have been prescribed Levoxyl 175 mcg tablets from the specific lot identified in this recall. Individuals relying on this exact dosage for thyroid hormone replacement are most at risk of receiving an ineffective dose.

How to tell if you have this one

Check your medication bottle for the following details: Brand name Levoxyl, strength 175 mcg, NDC 60793-859-01, and Lot # 24W06. The product is distributed in 100 tablet bottles by Pfizer Inc., New York, NY 10017, and was made in Austria. The expiration date on the bottle is 11/30/2026.

  • Brand
    Pfizer
  • Category
    Drug
FDA recall event · 2 products

All 2 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Ongoing
  • Distribution
    US Nationwide and Puerto Rico
Recall numberProduct, codes & lotsQuantity
D-0051-2027Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10; Lot # 24W07, Exp: 11/30/2026134 1000-count bottles
D-0052-2027Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.; Lot # 24W06, Exp: 11/30/202615,815 100-count bottles

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “US Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 29 days after the firm started it.

1. Firm started the recall: Sep 29, 202612. FDA classified it Class II: Oct 16, 202623. Published in FDA’s Enforcement Report: Oct 28, 202634. Added to GovInfoNow: Nov 3, 202642026
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. Added to GovInfoNow

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0052-2027 (September 29, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0052-2027 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on November 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA